BioLeap is a molecule design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful.
Collaboration
BioLeap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry. Learn more about how our technology can help solve your molecule discovery problems.
Technology
The BioLeap Advantage
BioLeap has engineered a revolutionary, performance-optimized fragment-based algorithm which results in a practical method for reliably determining how fragments bind. Learn More
News/Events
September 5, 2012
Fragment-Based Drug Design: Delivering Drugs That Hit Multiple targets, Leveraging Insights From Systems Biology | Read More
February 21, 2012
Fast Estimation of Solvation Free Energies for Diverse Chemical Species | Read More
February 3, 2012
A Fragment-based Approach to the SAMPL3 Challenge | Read More